TABLE 1.

Cytoplasmic peptidoglycan precursors and d,d-peptidase (VanX and VanY) activities in extracts from NY-VRSA and VRSA-5 strainsa

Strain and drug treatment% of peptidoglycan precursor:Activityb (nmol/min/mg protein) of:
UDP-MurNAc-tetrapeptideUDP-MurNAc- pentapeptide (d-Ala)UDP-MurNAc- pentapeptide (d-Lac)d,d-dipeptidase (cytoplasmic fraction)d,d-carboxypeptidase (membrane fraction)
NY-VRSA
    Uninduced595ND24 ± 63 ± 1
    VAN (6 μg/ml)181765502 ± 1555 ± 8
    TEC (4 μg/ml)151669294 ± 1626 ± 9
VRSA-5
    Uninduced496ND5 ± 1ND
    VAN (6 μg/ml)14ND86860 ± 5566 ± 4
    TEC (4 μg/ml)16ND84480 ± 3938 ± 3
  • a The cytoplasmic peptidoglycan precursors of NY-VRSA and VRSA-5 grown with or without glycopeptides were analyzed as described previously (19). Enzyme assays were performed with the S100 and C100 fractions of uninduced or induced cultures. VAN, vancomycin; TEC, teicoplanin. ND, not detectable.

  • b Values are means ± standard deviations.